NasdaqGS - Nasdaq Real Time Price USD

Design Therapeutics, Inc. (DSGN)

Compare
4.6800 -0.2400 (-4.88%)
At close: 4:00 PM EDT
4.5450 -0.13 (-2.88%)
After hours: 4:33 PM EDT
Loading Chart for DSGN
DELL
  • Previous Close 4.9200
  • Open 4.9200
  • Bid 4.6700 x 100
  • Ask 4.7300 x 100
  • Day's Range 4.6300 - 4.9200
  • 52 Week Range 1.9600 - 6.9100
  • Volume 156,688
  • Avg. Volume 268,909
  • Market Cap (intraday) 264.984M
  • Beta (5Y Monthly) 1.84
  • PE Ratio (TTM) --
  • EPS (TTM) -0.9000
  • Earnings Date Nov 11, 2024 - Nov 15, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 7.00

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

www.designtx.com

57

Full Time Employees

December 31

Fiscal Year Ends

Recent News: DSGN

View More

Research Reports: DSGN

View More

Performance Overview: DSGN

Trailing total returns as of 10/9/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

DSGN
76.60%
S&P 500
21.43%

1-Year Return

DSGN
103.48%
S&P 500
34.43%

3-Year Return

DSGN
68.10%
S&P 500
31.90%

5-Year Return

DSGN
87.45%
S&P 500
45.86%

Compare To: DSGN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: DSGN

View More

Valuation Measures

Annual
As of 10/8/2024
  • Market Cap

    278.57M

  • Enterprise Value

    20.26M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    1.07

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -13.63%

  • Return on Equity (ttm)

    -18.11%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -50.53M

  • Diluted EPS (ttm)

    -0.9000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    261.02M

  • Total Debt/Equity (mrq)

    1.04%

  • Levered Free Cash Flow (ttm)

    -33.75M

Research Analysis: DSGN

View More

Company Insights: DSGN

People Also Watch